Category: Cardiac ImplantsSyndicate content

New data not so good for Boston Scientific's Watchman anti-stroke device

September 22, 2014 by Scott Wooldridge

New data presented last week at the annual Transcatheter Cardiovascular Therapies meeting showed Boston Scienfitic's Watchman anti-stoke device to be comparable to treatment with the anti-coagulant warfarin.

New data not so good for Boston Scientific's Watchman anti-stroke device

St. Jude chases MRI-friendly labeling for its CRM devices

September 22, 2014 by Arezu Sarvestani

St. Jude Medical lands European approval to market its Tendril STS and IsoFlex Optim leads as safe for MRI scanning, adding that the company's just getting started on a larger MRI-safe campaign.

E.U. regulators dub St. Jude's Tendril STS, IsoFlex Optim leads safe with MRI

St. Jude cries victory with its quadripolar leads

September 4, 2014 by Arezu Sarvestani

St. Jude Medical says that its Quartet quadripolar leads "performed better than bipolar leads of any kind" in a recent mega-study.

St. Jude cries victory with its quadripolar leads

Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.

Pacemakers learn from wristwatches to ditch batteries

September 3, 2014 by Arezu Sarvestani

Another team of researchers is working on pacemakers that use motion for power, with aims to eliminate reliance on depletable batteries.

Pacemakers learn from wristwatches to ditch batteries

Swiss researchers are taking a page from their country's most iconic products to change how pacemakers are powered inside the body.

Medtronic launches personalized heart rhythm therapy trial

August 27, 2014 by Arezu Sarvestani

Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology.

Medtronic launches personalized heart rhythm therapy trial

Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific lands another date with FDA panel for Watchman stroke device

August 26, 2014 by Brad Perriello

An FDA advisory panel is slated to convene yet again in October to consider the safety and efficacy of Boston Scientific's Watchman anti-stroke heart repair device.

Boston Scientific lands another date with FDA panel for Watchman stroke device
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp